The Northwestern University Robert H. Lurie Cancer Center is an NCl- designated clinical cancer center which conducts a broad range of multidisciplinary clinical and laboratory research. The Cancer Center integrates the expertise and resources of the Medical School and its five affiliated hospitals along with those of departments located on the University's Evanston campus. Established in 1974, the Lurie Cancer Center functions as a full organizational unit with the status of a department of the Medical School. The Center's specific authorities and responsibilities are reflected in the goals that were defined when the Center was established and have been maintained since that time: l. To coordinate and integrate the cancer and cancer-related activities of the University. 2. To conduct and support cancer research and to integrate cancer-related research throughout the University. 3. To develop and conduct cancer education programs. 4. To participate in the care of cancer patients at the affiliated hospitals of the McGaw Medical Center of NU. 5. To develop and implement initiatives in cancer prevention and control research. These goals are accomplished through the activities of 6 established programs and 11 shared resources. PROGRAMS 1. Molecular Oncogenesis 2. Adhesion, Motility, and Angiogenesis 3. Hormone Action and Signal Transduction 4. Differentiation and Development 5. Clinical Investigations 6. Cancer Prevention and Control Research SHARED RESOURCES 1. Media Prep Facility 2. Flow Cytometry 3. Transgenic Facility 4. 2-D Gel Facility 5. Research Histology 6. DNA-Protein Comp Facility 7. Biotechnology Facility 8. Cell Imaging Facility 9. Monoclonal Antibody Facility 10. Biometry 11. Clinical Research Office

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA060553-06S2
Application #
6085813
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Project Start
1993-08-01
Project End
2001-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Buglak, Nicholas E; Jiang, Wulin; Bahnson, Edward S M (2018) Cinnamic aldehyde inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in Zucker Diabetic Fatty rats. Redox Biol 19:166-178
Yang, Ruiguo; LemaƮtre, Vincent; Huang, Changjin et al. (2018) Monoclonal Cell Line Generation and CRISPR/Cas9 Manipulation via Single-Cell Electroporation. Small 14:e1702495
Takahashi, Satoe; Sun, Willy; Zhou, Yingjie et al. (2018) Prestin Contributes to Membrane Compartmentalization and Is Required for Normal Innervation of Outer Hair Cells. Front Cell Neurosci 12:211
Zheng, Jianbin; Chen, Long; Skinner, Owen S et al. (2018) ?-Glucocerebrosidase Modulators Promote Dimerization of ?-Glucocerebrosidase and Reveal an Allosteric Binding Site. J Am Chem Soc 140:5914-5924
Kenney, Grace E; Dassama, Laura M K; Pandelia, Maria-Eirini et al. (2018) The biosynthesis of methanobactin. Science 359:1411-1416
Joyce, Brian T; Zheng, Yinan; Zhang, Zhou et al. (2018) miRNA-Processing Gene Methylation and Cancer Risk. Cancer Epidemiol Biomarkers Prev 27:550-557
Chu, Lan H; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A et al. (2018) The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun 9:996
Symes, Yael R; Barrington, Clare; Austin, Jane et al. (2018) Advice to patients undergoing stem cell transplant: Content analysis of survivor peer support narratives. J Health Psychol 23:818-828
Lewis, Phillip L; Green, Richard M; Shah, Ramille N (2018) 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. Acta Biomater 69:63-70
Ugolkov, Andrey V; Bondarenko, Gennadiy I; Dubrovskyi, Oleksii et al. (2018) 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs 29:717-724

Showing the most recent 10 out of 1972 publications